FDA denies accelerated approval of Genentech's trastuzumab-DM1 (T-DM1) BLA for metastatic breast cancer
In its review of the BLA, the FDA stated the T-DM1 trials did not meet the standard for accelerated approval because all available treatment choices approved for metastatic breast cancer, regardless of HER2 status, had not been exhausted in the study population.
Use The Common Cold Virus To Target And Disrupt Cancer Cells?
A novel mechanism used by adenovirus to sidestep the cell's suicide program, could go a long way to explain how tumor suppressor genes are silenced in tumor cells and pave the way for a new type of targeted cancer therapy, report researchers at the Salk Institute for Biological Studies in the Aug. 26, 2010 issue of Nature. When a cell is under stress, the tumor suppressor p53 springs into action ...
Clinical Trials Update: Sept. 1, 2010
(HealthDay News) -- Here are the latest clinical trials, courtesy of ClinicalConnection.com:
MS patient criticizes decision to defer clinical trials on new treatment
Tony Tavares was surprised to hear the federal government wonGCOt back clinical trials for a new MS treatment, especially considering the many amazing testimonials from patients paying for the procedure internationally.
Opposition calls decision to withhold funding for MS clinical trials 'devastating'
Opposition critics say the decision by the federal government not to fund Canada-wide clinical trials of a controversial multiple sclerosis treatment is a huge setback for the thousands of patients suffering from the debilitating neurological disorder.
